Oruka Therapeutics, Inc. (ORKA) on Monday reported positive interim results from its Phase 2a EVERLAST-A trial of ORKA-001 in moderate-to-severe plaque psoriasis. The company's shares rose more than 20% in pre-market trading.
In the study, 63.5% of patients treated with ORKA-001 achieved PASI 100 at Week 16, indicating complete skin clearance, with similar results seen on the Investigator's Global Assessment (IGA 0). Further, ORKA-001 was well tolerated, with no serious treatment-emergent adverse events reported.
Oruka said it plans to share longer-term data from the trial, including Week 28 efficacy and 52-week follow-up for some patients, in the second half of 2026. The company is also advancing its Phase 2b EVERLAST-B trial, with results expected in 2027.
"These data reached the top end of what we could have expected from ORKA-001 across efficacy, tolerability, and potential for long-lasting response," said Joana Goncalves, MBChB, Chief Medical Officer of Oruka.
Oruka stock closed at $69.03 on Friday, up 1.90%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.